Kairos Pharma Ltd. (NYSE American: KAPA) announced its participation in the DealFlow Discovery Conference scheduled for January 28–29, 2026, at the Borgata Hotel, Casino & Spa in Atlantic City, New Jersey. The company's Chief Scientific Officer, Neil Bhowmick, will deliver a company presentation and conduct one-on-one meetings with investors during the event. This participation comes as Kairos continues to advance its clinical-stage oncology programs, which are focused on addressing significant challenges in cancer treatment.
The importance of this announcement lies in the ongoing development of Kairos Pharma's lead candidate, ENV-105, an antibody designed to target CD105—a protein identified as a key driver of resistance and disease relapse in response to standard cancer therapies. By targeting CD105, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard treatments across multiple cancer types. This approach could potentially improve outcomes for patients who have developed resistance to existing therapies, a common and serious problem in oncology.
Currently, ENV-105 is being evaluated in two clinical trials: a Phase 2 trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer. These trials address significant unmet medical needs in two prevalent and often difficult-to-treat cancers. It is important to note that, as of the date of the press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any comparable foreign regulator. The latest news and updates relating to KAPA are available in the company’s newsroom at https://ibn.fm/KAPA.
The implications of Kairos Pharma's conference participation and pipeline progress are multifaceted. For the biotechnology and pharmaceutical industry, successful development of therapies like ENV-105 could introduce new treatment paradigms for managing drug-resistant cancers, potentially opening new markets and driving innovation in oncology research. For investors, events like the DealFlow Discovery Conference provide critical opportunities to assess the company's scientific progress, management strategy, and long-term viability in a competitive field.
For patients and the healthcare system, advancements in overcoming drug resistance represent a crucial step forward. Cancer remains a leading cause of death worldwide, and resistance to therapy is a major barrier to improving survival rates and quality of life. Therapies that can resensitize tumors to standard treatments may offer new hope for patients with limited options, potentially reducing healthcare costs associated with ineffective treatments and disease progression. The full press release can be viewed at https://ibn.fm/0CBmk.
Kairos Pharma's work exemplifies the ongoing shift in oncology toward targeted therapies that address specific mechanisms of treatment failure. As the company prepares to present at the DealFlow Discovery Conference, its progress will be closely watched by the medical and investment communities, highlighting the continuous need for innovation in the fight against cancer.
